Bevacizumab, an anti-VEGF humanized murine monoclonal antibody, is effective in inhibiting GAMs and Tregs and increasing CTL infiltration, thereby restores the supportive immune microenvironment in glioblastoma (58). Here, VEGFA is linked to glioblastoma.